Overexpression of Ephrin A3 Receptor in Canine Prostatic Carcinoma

被引:4
|
作者
Hood, G. [1 ]
Laufer-Amorim, R. [2 ]
Fonseca-Alves, C. E. [2 ]
Palmieri, C. [1 ]
机构
[1] Univ Queensland, Sch Vet Sci, Gatton Campus, Gatton, Qld, Australia
[2] Univ Estadual Paulista, Sch Vet Med & Anim Sci, Sao Paulo, Brazil
关键词
cancer; dog; EphA3; prostate; RETROSPECTIVE ANALYSIS; THERAPEUTIC TARGET; EPHA3; CELL; EXPRESSION; CANCER; GENE; IDENTIFICATION; PROGRESSION; ADHESION;
D O I
10.1016/j.jcpa.2016.01.002
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Ephrin A3 (EphA3), a member of the ephrin receptor tyrosine kinase family, is involved in a variety of functions in normal cells, especially during embryonic development, and alterations in its expression profile have been observed in several human cancers. However, there are no reports of the expression of EphA3 in normal, hyperplastic or neoplastic canine prostate tissue or in other types of canine tumours. Six normal, 15 hyper plastic and 21 neoplastic canine prostates were examined immunohistochemically with a polyclonal antibody specific for human EphA3. The percentage of positive cells in all prostatic carcinomas was increased, with a mean of 89.28 +/- 5.18% compared with normal (9.17 +/- 6.72%) and hyperplastic prostates (20.00 +/- 8.28%). EphA3 expression was not correlated with the histological subtypes of prostate cancer or with the Gleason score. The increase in EphA3 expression in canine prostatic carcinomas suggests the involvement of this receptor in prostatic carcinogenesis and its potential use as a target for new therapeutic strategies. (C) 2016 Elsevier Ltd. All rights reserved.
引用
收藏
页码:180 / 185
页数:6
相关论文
共 50 条
  • [31] Decoy Receptor 3 Overexpression and Immunologic Tolerance in Hepatocellular Carcinoma (HCC) Development
    Chen, Caixia
    Zhang, Changgong
    Zhuang, Guohong
    Luo, Hongfang
    Su, Jinhua
    Yin, Pinh
    Wang, Juan
    CANCER INVESTIGATION, 2008, 26 (10) : 965 - 974
  • [32] The A3 adenosine receptor (A3AR) as a surrogate marker and therapeutic target in hepatocellular carcinoma (HCC).
    Fishman, P
    Bar Yehuda, S
    Stemmers, S
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 9146S - 9146S
  • [33] Allosteric modulators of the A3 adenosine receptor
    Jacobson, Kenneth A.
    IJzerman, Adriaan P.
    Auchampach, John A.
    Gao, Zhan-Guo
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2011, 242
  • [34] THE HUMAN A3 ADENOSINE RECEPTOR GENE
    MURRISON, E
    GOODSON, SJ
    HARRIS, CA
    EDBROOKE, MR
    BIOCHEMICAL SOCIETY TRANSACTIONS, 1995, 23 (02) : S270 - S270
  • [35] Cardioprotection with A3 adenosine receptor agonists
    Auchampach, JA
    DRUG DEVELOPMENT RESEARCH, 2002, 56 (04) : 550 - 550
  • [36] The A3 Adenosine Receptor: History and Perspectives
    Borea, Pier Andrea
    Varani, Katia
    Vincenzi, Fabrizio
    Baraldi, Pier Giovanni
    Tabrizi, Mojgan Aghazadeh
    Merighi, Stefania
    Gessi, Stefania
    PHARMACOLOGICAL REVIEWS, 2015, 67 (01) : 74 - 102
  • [37] Cardioprotection with A3 adenosine receptor agonists
    Auchampach, JA
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2003, 35 (06) : A6 - A6
  • [38] Overexpression of retinoic acid receptor α in hepatocellular carcinoma
    Sano, K
    Takayama, T
    Murakami, K
    Saiki, I
    Makuuchi, M
    CLINICAL CANCER RESEARCH, 2003, 9 (10) : 3679 - 3683
  • [39] Laparoscopic-assisted cutaneous ureterostomy in a canine patient with prostatic carcinoma
    Allevi, Giovanni
    Spediacci, Carlotta
    Marchesi, Elena
    Trovatelli, Marco
    VETERINARY MEDICINE AND SCIENCE, 2021, 7 (05) : 1483 - 1487
  • [40] Epithelial and stromal androgen receptor expression in prostatic carcinoma and benign prostatic hyperplasia
    Filipovski, V.
    Kubelka-Sabit, K.
    Janevska, V.
    Jasar, D.
    VIRCHOWS ARCHIV, 2015, 467 : S274 - S275